NAD+ is not a peptide. It is nicotinamide adenine dinucleotide, a coenzyme that helps cells carry out chemical reactions. You will often find it alongside peptide therapies, but grouping them together does not make them the same kind of molecule.
NAD is essential to metabolism, but that doesn’t prove an infusion improves energy, memory or aging. Keep three subjects separate: NAD inside cells, direct NAD+ treatment, and supplements the body uses to make NAD.
What does NAD+ do in the body?
Think of NAD as a reusable carrier in the reactions that help turn food into usable energy. NAD+ accepts electrons and becomes NADH; NADH can pass those electrons along. These reactions are part of the cell’s energy-production machinery, including pathways connected to mitochondria. NAD is also used in cellular signaling and DNA-repair processes. [1]
Your body can make NAD from dietary building blocks, including forms of vitamin B3 and tryptophan. Getting enough of those nutrients matters, but correcting a deficiency is a different question from giving extra NAD to someone who already has adequate nutrition. [1]
NAD+, NADH, NR and NMN are not interchangeable
| Name | What to know |
|---|---|
| NAD+ and NADH | Two chemical forms involved in electron-transfer reactions. The plus sign is part of the chemistry, not a stronger product grade. [1] |
| NR | Nicotinamide riboside, a precursor studied as an oral supplement. An NR trial is not an NAD+ injection trial. [3] |
| NMN | Nicotinamide mononucleotide, another precursor. Its clinical studies must also be read on their own terms. [4] |
A useful first question about any “NAD study” is therefore: What did the participants actually receive? Check the substance, the route and the outcome before applying its findings to a different treatment.
Related dosage pages: For vial-specific concentration, reconstitution, and measurement examples, see NAD+ (500 mg Vial) Dosage Protocol and NAD+ (1000 mg Vial) Dosage Protocol. Each linked protocol remains a separate reference because vial strength changes concentration and syringe-unit calculations.
What benefits have human studies found?
There are encouraging findings about NAD-related metabolism, but they are more specific than a general promise of rejuvenation. These four studies illustrate both the progress and the limits. They are selected examples, not an exhaustive review of every NAD-related trial.
| Study and treatment | Result and limitation |
|---|---|
| Grant, 2019 Direct IV NAD+ |
Eleven men: eight received NAD+ and three saline. Researchers tracked blood and urine metabolites around a six-hour infusion. This was not a test of improved energy, cognition or lifespan. [2] |
| Martens, 2018 Oral NR |
Twenty-four adults completed a placebo-controlled crossover trial with two six-week periods. Blood-cell NAD+ increased. The study did not establish longer life or broad clinical benefit. [3] |
| Yoshino, 2021 Oral NMN |
Twenty-five postmenopausal women with prediabetes were studied for ten weeks. Muscle insulin sensitivity improved, but body fat and several other metabolic measures did not. This does not establish the same result in everyone or with injections. [4] |
| Igarashi, 2026 Oral NMN |
A 24-week trial in adults aged 65 or older raised blood NAD-related metabolites, but did not significantly improve hearing, the primary endpoint, or physical performance. [5] |
What the September 2026 study adds
The newest study above makes the difference between a blood marker and a health benefit especially clear. Some secondary measures initially appeared to change, but the findings did not remain statistically significant after adjustment for testing multiple outcomes. They are leads for further research, not confirmed benefits. The article was released as an accepted early publication on September 25, 2026; it reports supplier funding and relevant author financial interests. [5]
That is not a reason to dismiss all NAD research. It is a reason to ask a better question than “Did NAD go up?” The question is whether people experienced a meaningful benefit from the particular intervention being considered.
Quick check: NAD levels rose. Does that mean the treatment reversed aging?
No. A biochemical change can show that a treatment affected a pathway without showing that people lived longer or functioned better. The 2026 NMN trial raised circulating NAD-related metabolites without a significant improvement in its primary clinical endpoint. [5]
What do we know about NAD+ injections and infusions?
The direct-infusion pilot is useful for understanding what happened to NAD and its breakdown products in blood and urine. No adverse events were observed during the infusion in that small study. But eight treated participants and a short observation period cannot establish long-term safety, detect uncommon harms or prove that an infusion treats fatigue. [2]
It is also important not to transfer findings between routes. An IV infusion, a subcutaneous injection and an oral precursor are different interventions. A paper on one does not automatically validate the others. If a treatment is advertised using an NR or NMN study, ask to see evidence for the actual product and route being offered.
Safety and side effects: the product matters too
The FDA has received reports of severe chills, shaking, vomiting and fatigue after NAD+ injectable drugs, with some people requiring medical treatment. Its notice says these reactions are consistent with excessive endotoxin levels and warns compounders about using ingredients unsuitable for sterile preparations. [6]
This is a specific product-quality concern. It does not establish how often every NAD+ formulation causes a reaction, and it should not be rebranded as a harmless “detox” response. Food-grade material is not automatically suitable for injection.
Before considering an injectable product, discuss its source, preparation standards, expected benefit and adverse-event plan with a qualified clinician. If you develop severe symptoms during or after a treatment, seek medical attention rather than relying on a general wellness explanation.
Is there a standard NAD+ dose for energy or longevity?
The studies reviewed here do not establish a universal dose or schedule for those goals. An amount used in a small metabolism experiment is not automatically an effective treatment dose, and a precursor trial cannot supply an injection regimen.
The linked NAD+ protocol pages address vial-specific reference information. Knowing a vial’s contents or how concentration is calculated does not answer whether an intervention is appropriate for a particular person. That requires a separate clinical judgment.
Five questions worth asking before NAD+ therapy
- What problem are we trying to address? A clear symptom or diagnosis is more useful than an undefined goal of “cellular optimization.”
- Which compound and route are proposed? Direct NAD+, NR and NMN need separate evidence.
- What improved in the relevant human trial? Look beyond a higher blood marker to the outcome you care about.
- How will we judge whether it helped? Agree on a meaningful measure and a review point rather than assuming an ongoing treatment is beneficial.
- What are the risks and alternatives? Review health conditions, medicines, product quality and other explanations for symptoms with your clinician.
The takeaway
Some human interventions change NAD-related markers, and particular precursor trials have reported selected benefits. That isn’t proof that NAD+ injections reverse aging or reliably improve energy and memory. Check the molecule, route and measured outcome behind each claim.
Related dosage protocols and research
Explore related research, dosage references and guides below. Vial strengths have separate references because concentration and syringe-unit calculations differ. A comparison does not mean the compounds are interchangeable.
Matching dosage protocols
Related protocols and comparisons
Further research context
References
- NIH Office of Dietary Supplements. Niacin: fact sheet for health professionals. NAD biology and dietary precursors.
- Grant R, et al. Human plasma and urine NAD+ metabolites during a six-hour IV infusion: a pilot study. Frontiers in Aging Neuroscience. 2019. DOI: 10.3389/fnagi.2019.00257.
- Martens CR, et al. Nicotinamide riboside supplementation in middle-aged and older adults. Nature Communications. 2018. DOI: 10.1038/s41467-018-03421-7.
- National Institutes of Health. NMN and glucose metabolism in women’s muscle. Research summary of Yoshino et al., Science, 2021. Primary study DOI: 10.1126/science.abe9985.
- Igarashi M, et al. Sustained NAD+ augmentation with NMN: a 24-week randomized trial. npj Aging. Accepted early article, September 25, 2026. DOI: 10.1038/s41514-026-00482-7.
- U.S. Food and Drug Administration. Ingredients suitable for sterile compounding. NAD+ injectable-drug safety notice; checked October 6, 2026.